Christopher O’Brien

3.9k total citations · 1 hit paper
70 papers, 2.8k citations indexed

About

Christopher O’Brien is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Christopher O’Brien has authored 70 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 33 papers in Hepatology and 8 papers in Surgery. Recurrent topics in Christopher O’Brien's work include Liver Disease Diagnosis and Treatment (22 papers), Hepatitis C virus research (19 papers) and Liver Disease and Transplantation (13 papers). Christopher O’Brien is often cited by papers focused on Liver Disease Diagnosis and Treatment (22 papers), Hepatitis C virus research (19 papers) and Liver Disease and Transplantation (13 papers). Christopher O’Brien collaborates with scholars based in United States, United Kingdom and Belgium. Christopher O’Brien's co-authors include James Zangrilli, Philip G. Bardin, Mario Castro, Michael E. Wechsler, Eric D. Bateman, Stephanie Korn, Guy Brusselle, Kevin Murphy, Jorge Máspero and Dong Li and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Christopher O’Brien

65 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

2015 840 citations Mario Castro, James Zangrilli et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher O’Brien United States	26	927	860	811	598	487	70	2.8k
Claire O’Brien United Kingdom	31	560 0.6×	639 0.7×	401 0.5×	348 0.6×	454 0.9×	143	5.6k
Jean‐Noël Talbot France	38	288 0.3×	709 0.8×	246 0.3×	1.7k 2.8×	970 2.0×	232	5.5k
Moshe Leshno Israel	34	304 0.3×	770 0.9×	334 0.4×	541 0.9×	1.1k 2.3×	151	4.3k
Dong‐Hoon Yang South Korea	44	176 0.2×	1.8k 2.1×	123 0.2×	1.6k 2.6×	2.1k 4.2×	374	6.8k
TK Chan China	26	127 0.1×	719 0.8×	88 0.1×	113 0.2×	97 0.2×	120	2.6k
Chung‐Jen Chen Taiwan	35	58 0.1×	450 0.5×	144 0.2×	131 0.2×	228 0.5×	166	4.3k
David Talbot United Kingdom	32	686 0.7×	214 0.2×	30 0.0×	344 0.6×	1.9k 3.9×	245	4.5k
Josep Llach Spain	45	2.2k 2.4×	2.4k 2.8×	98 0.1×	1.4k 2.3×	3.1k 6.3×	233	7.4k
Antonella Petrillo Italy	42	1.2k 1.2×	507 0.6×	48 0.1×	1.1k 1.8×	992 2.0×	275	5.9k
William L. Berry United States	37	48 0.1×	173 0.2×	135 0.2×	503 0.8×	202 0.4×	131	5.4k

Countries citing papers authored by Christopher O’Brien

Since Specialization

Citations

This map shows the geographic impact of Christopher O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher O’Brien more than expected).

Fields of papers citing papers by Christopher O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher O’Brien. The network helps show where Christopher O’Brien may publish in the future.

Co-authorship network of co-authors of Christopher O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher O’Brien. A scholar is included among the top collaborators of Christopher O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher O’Brien. Christopher O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Brien, Christopher, et al.. (2025). A bibliometric analysis of ethical leadership and sustainable performance. International Journal of Ethics and Systems.

Ferreira, Raphaella, Gennaro Selvaggi, Akin Tekin, et al.. (2023). Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant. Cancers. 15(12). 3165–3165. 3 indexed citations

Rudrapatna, Vivek A., Yao‐Wen Cheng, Jonathan Shih, et al.. (2023). Creation of an ustekinumab external control arm for Crohn’s disease using electronic health records data: A pilot study. PLoS ONE. 18(3). e0282267–e0282267. 7 indexed citations

Kollmeier, Alexa P., Elliot S. Barnathan, Christopher O’Brien, et al.. (2018). A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma. Annals of Allergy Asthma & Immunology. 121(5). 568–574. 16 indexed citations

Castro, Mario, James Zangrilli, Michael E. Wechsler, et al.. (2015). Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. The Lancet Respiratory Medicine. 3(5). 355–366. 840 indexed citations breakdown →

Corren, Jonathan, Steven F. Weinstein, Lindsay Janka, Christopher O’Brien, & James Zangrilli. (2014). A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. European Respiratory Journal. 44(Suppl 58). 4673–4673. 13 indexed citations

O’Brien, Christopher, et al.. (2014). Hepatotoxicity Secondary to Chemotherapy. Journal of Clinical and Translational Hepatology. 2(2). 95–102. 133 indexed citations

Levy, Cynthia, Jahnavi Naik, Christopher O’Brien, et al.. (2013). Hispanics With Primary Biliary Cirrhosis Are More Likely to Have Features of Autoimmune Hepatitis and Reduced Response to Ursodeoxycholic Acid Than Non-Hispanics. Clinical Gastroenterology and Hepatology. 12(8). 1398–1405. 51 indexed citations

O’Brien, Christopher. (2009). The Hospitalized Patient with Abnormal Liver Function Tests. Clinics in Liver Disease. 13(2). 179–192. 3 indexed citations

10.

Arora, Sanjeev, Christopher O’Brien, Stefan Zeuzem, et al.. (2006). Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α‐2a (40 kDa) plus ribavirin: Impact on health‐related quality of life. Journal of Gastroenterology and Hepatology. 21(2). 406–412. 40 indexed citations

11.

Prati, Daniele, Mitchell L. Shiffman, M. Diago, et al.. (2006). Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. Journal of Hepatology. 44(4). 679–685. 34 indexed citations

12.

Neff, Guy, Christopher O’Brien, Robert Cirocco, et al.. (2004). Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transplantation. 10(5). 595–598. 25 indexed citations

13.

Neff, Guy, Christopher O’Brien, Jose Nery, et al.. (2004). Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transplantation. 10(12). 1497–1503. 47 indexed citations

14.

Neff, Guy, et al.. (2004). Topical testosterone treatment for chronic allograft failure in liver transplant recipients with recurrent hepatitis C virus. Transplantation Proceedings. 36(10). 3071–3074. 9 indexed citations

15.

Neff, Guy, Christopher O’Brien, Marzia Montalbano, et al.. (2004). CASE REPORT: Beneficial Effects of Topical Testosterone Replacement in Patients with End-Stage Liver Disease. Digestive Diseases and Sciences. 49(7-8). 1186–1189. 6 indexed citations

16.

Pockros, Paul J., Keyur Patel, Christopher O’Brien, et al.. (2003). A Multicenter Study of Recombinant Human Interleukin 12 for the Treatment of Chronic Hepatitis C Virus Infection in Patients Nonresponsive to Previous Therapy. Hepatology. 37(6). 1368–1374. 25 indexed citations

17.

Feun, Lynn G., Christopher O’Brien, Enrique Molina, et al.. (2003). Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial. Journal of Cancer Research and Clinical Oncology. 129(1). 17–20. 10 indexed citations

18.

O’Brien, Christopher, et al.. (1999). Extracorporeal Photopheresis Alone and with Interferon-α2a in Chronic Hepatitis C Patients Who Failed Previous Interferon Therapy. Digestive Diseases and Sciences. 44(5). 1020–1026. 5 indexed citations

19.

Kato, Tomoaki, et al.. (1999). The first case report of the use of a zoom videoendoscope for the evaluation of small bowel graft mucosa in a human after intestinal transplantation. Gastrointestinal Endoscopy. 50(2). 257–261. 35 indexed citations

20.

Moonka, Dilip, et al.. (1998). Quantitative assessment of hepatitis C virus RNA in peripheral blood mononuclear cells during therapy with interferon‐α2a. Journal of Viral Hepatitis. 5(1). 27–33. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact